Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

주식 순위 #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
주가
$6.89
시가총액
$43.94B
변동 (1일)
-2.91%
변동 (1년)
-24.78%
국가
CN
거래 Jiangsu Hengrui Medicine Co., Ltd. (600276)

카테고리

Healthcare
Jiangsu Hengrui Medicine Co., Ltd. (600276)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 4.71
Jiangsu Hengrui Medicine Co., Ltd.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 4.71입니다. 2024년 말 기준 P/B 비율은 6.39였습니다.
Jiangsu Hengrui Medicine Co., Ltd.의 P/B 비율 기록 (2001 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) 4.71 -25.48%
2025 6.32 -1.09%
2024 6.39 -9.65%
2023 7.07 9.04%
2022 6.49 -29.84%
2021 9.24 -52.24%
2020 19.35 24.50%
2019 15.55 57.24%
2018 9.89 -5.23%
2017 10.43 45.32%
2016 7.18 -10.85%
2015 8.05 63.76%
2014 4.92 -13.09%
2013 5.66 13.80%
2012 4.97 -8.81%
2011 5.45 -40.25%
2010 9.12 4.84%
2009 8.70 25.59%
2008 6.93 -35.14%
2007 10.68 89.97%
2006 5.62 451.70%
2005 1.02 5.76%
2004 0.96 -9.87%
2003 1.07 -10.67%
2002 1.20 -6.19%
2001 1.28 0.00%
유사 기업 또는 경쟁사의 P/B 비율